Subtype
Head and Neck Mucosal Squamous Cell Carcinoma
CI-CAN-00002825Explore in graph →
160 active trials3 evidence items
- NCIt
- C214954
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002825Explore in graph →
Clinical trials
457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (60)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 |
| clinicaltrials |
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT02295540 | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity(PRIMED-001) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 1 | Mar 20, 2015 | clinicaltrials |
| NCT01718223 | Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Sep 3, 2014 | clinicaltrials |
| NCT01728480 | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 11, 2013 | clinicaltrials |
| NCT00095641 | S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 8, 2013 | clinicaltrials |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | May 15, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2025source: clinicaltrials